Preferred
(EDT)
Other
Therapeutics II: In Vivo Editing
Development of crPhage to Treat Infections
5:00 PM - 5:25 PM EST
Tuesday, March 9, 2021Speaker
David Ousterout, PhD
Locus Biosciences, Inc.
Therapeutics II: In Vivo Editing
Towards a CRISPRi/a Therapeutic for Radiation Injury
5:25 PM - 5:50 PM EST
Tuesday, March 9, 2021Speaker
Fyodor Urnov, PhD
University of California, Berkeley
Therapeutics II: In Vivo Editing
Engineering AAV for Targeted In Vivo Editing
5:50 PM - 6:15 PM EST
Tuesday, March 9, 2021Speaker
Aravind Asokan, PhD
Duke University
Delivery
Coffee Break
6:15 PM - 6:35 PM EST
Tuesday, March 9, 2021Therapeutics II: In Vivo Editing
Epigenome Regulation for Treatment of Chronic Pain
6:35 PM - 7:00 PM EST
Tuesday, March 9, 2021Speaker
Ana Moreno Collado, PhD
Navega Therapeutics
Therapeutics II: In Vivo Editing
Short Talk: A Versatile Platform for ADAR-Mediated RNA Editing in vivo in Preclinical Models
7:00 PM - 7:15 PM EST
Tuesday, March 9, 2021Speaker
Chikdu Shivalila, PhD
Wave Life Sciences
Therapeutics II: In Vivo Editing
Short Talk: Upregulation of Disease Compensatory Gene via CRISPR Activation in Muscular Dystrophy Mice
7:15 PM - 7:30 PM EST
Tuesday, March 9, 2021Speaker
Jia Qi Cheng-Zhang, MS
University of Pittsburgh
Therapeutics II: In Vivo Editing
Short Talk: CRISPR Activation to Rescue SCN2A Haploinsufficiency in Autism Spectrum Disorder
7:30 PM - 7:45 PM EST
Tuesday, March 9, 2021Speaker
Serena Tamura, BA
University of California San Francisco
Therapeutics II: In Vivo Editing
